Terms: = Uterine cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346
698 results:
1. Endometrial cytological findings for a mesonephric-like endometrial adenocarcinoma: A case report.
Omine H; Ishida K; Sasaki N; Kato H; Nagai T; Ishikawa M; Takaoka M; Noda S; Matsuda H; Mitsuhashi A
Diagn Cytopathol; 2024 Jun; 52(6):E129-E133. PubMed ID: 38454318
[TBL] [Abstract] [Full Text] [Related]
2. Dosimetric Comparison of Isodose Surface Volume and Total Reference Air Kerma (TRAK) based Volume in Cervical cancer Brachytherapy.
Thimmaiah N; Malavade V; A S UK; S S; Pasha C R T; Vishwanath L
Asian Pac J Cancer Prev; 2024 Feb; 25(2):587-594. PubMed ID: 38415545
[TBL] [Abstract] [Full Text] [Related]
3. Patterns of practice survey for cervical cancer brachytherapy in Morocco.
Chekrine T; Bellefkih FZ; Hatim G; Bouchbika Z; Benchakroun N; Jouhadi H; Tawfiq N; Sahraoui S
Brachytherapy; 2024; 23(2):154-164. PubMed ID: 38311545
[TBL] [Abstract] [Full Text] [Related]
4. Ovarian non-gestational placental site trophoblastic tumor with lung metastasis: further evidence for a distinct category of trophoblastic neoplasm.
Shahi M; Katsakhyan L; Hopkins M; Allen-Rhoades W; Cepress MK; Langstraat C; Ishitani MB; Vang R; Ronnett BM; Xing D
Diagn Pathol; 2024 Jan; 19(1):3. PubMed ID: 38172961
[TBL] [Abstract] [Full Text] [Related]
5. Redefining the role of pulsed-dose-rate brachytherapy in cervical cancer treatment using a preplanned approach.
Annede P; Robert C; Espenel S; Dumas I; Chargari C
Brachytherapy; 2024; 23(2):107-114. PubMed ID: 38105154
[TBL] [Abstract] [Full Text] [Related]
6. Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US.
Hsieh K; Bloom JR; Dickstein DR; Hsieh C; Marshall D; Ghiassi-Nejad Z; Raince J; Lymberis S; Chadha M; Gupta V
Gynecol Oncol; 2024 Jan; 180():55-62. PubMed ID: 38052109
[TBL] [Abstract] [Full Text] [Related]
7. Simultaneous catheter and multicriteria optimization for hdr cervical cancer brachytherapy with a complex intracavity/interstitial applicator.
Bélanger C; Aubin S; Lavallée MC; Beaulieu L
Med Phys; 2024 Mar; 51(3):2128-2143. PubMed ID: 38043067
[TBL] [Abstract] [Full Text] [Related]
8. Image-guided high-dose-rate brachytherapy as the method of choice in medically inoperable early-stage endometrial cancer patients.
Rydzinski M; Bijok M; Michalski W; Kowalczyk A; Gruszczynska E; Zolciak-Siwinska A
Gynecol Oncol; 2024 Jan; 180():6-13. PubMed ID: 38035868
[TBL] [Abstract] [Full Text] [Related]
9. Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and hdr brachytherapy boost in cervical cancer.
Dincer N; Ugurluer G; Mustafayev TZ; Serkizyan A; Aydin G; Güngör G; Yapici B; Atalar B; Özyar E
Brachytherapy; 2024; 23(1):18-24. PubMed ID: 38000958
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy of high-dose-rate brachytherapy with different radiation source activities among cervical cancer patients and risk factors for long-term outcomes: A 6-year retrospective study.
Wen F; Li C; Liang B; You J; Li X; Wang J; Liu H; Wang F; Dong Z; Zhang Y
Brachytherapy; 2024; 23(1):35-44. PubMed ID: 37919124
[TBL] [Abstract] [Full Text] [Related]
11. External Beam Radiotherapy Interdigitated with High Dose Rate(hdr) Intracavitary Brachytherapy versus External Beam Radiotherapy followed by Sequential hdr Intracavitary Brachytherapy for Locally Advanced Carcinoma Cervix-Randomized Control Study.
Gupta IJ; Ghosh A; Yadav J; Tuteja JS; Gupta R; Srivastava K; Verma M; Gupta S; Srivastava S; Bhatt MLB
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3441-3445. PubMed ID: 37898849
[TBL] [Abstract] [Full Text] [Related]
12. Interfraction variations in doses at OARs during three-dimensional high dose rate brachytherapy planning of cervix cancer.
Dhaka S; Rajani A; Kumar HS; Sharma N; Jakhar SL; Harsh K
J Cancer Res Ther; 2023; 19(5):1136-1141. PubMed ID: 37787275
[TBL] [Abstract] [Full Text] [Related]
13. The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle-income countries.
Grover S; Lichter KE; Likhacheva A; Jang JW; Ning MS; Robin TP; Small W; Kudchadker RJ; Swamidas J; Chopra S; Rai B; Sharma SD; Sharma DN; Kuppusamy T; Yang R; Berger D; Mendez LC; Glaser S; Erickson DL; Chino J; Mourtada F; Abdel-Wahab M; Jhingran A; Simonds H; Mahantshetty U
Brachytherapy; 2023; 22(6):716-727. PubMed ID: 37704540
[TBL] [Abstract] [Full Text] [Related]
14. The population percentile allowance method for determining systematic spatial error tolerances for temporary intensity modulated brachytherapy.
Hopfensperger KM; Adams QE; Kim Y; Wu X; Xu W; Patwardhan K; Flynn RT
Med Phys; 2023 Oct; 50(10):6469-6478. PubMed ID: 37643427
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma.
Lee Y; Choi S; Kim HS
Int J Gynecol Pathol; 2024 May; 43(3):221-232. PubMed ID: 37566876
[TBL] [Abstract] [Full Text] [Related]
16. Brachytherapy for targeting the immune system in cervical cancer patients.
Linares I; Berenguer Frances MÁ; Cañas R; Najjari D; Gutiérrez C; Marín S; Comas S; Guedea F; Pujol M
BMC Immunol; 2023 Aug; 24(1):23. PubMed ID: 37559025
[TBL] [Abstract] [Full Text] [Related]
17. A linear optimization model for high dose rate brachytherapy using a novel distance metric.
Mirzavand Boroujeni N; Richard JP; Sterling D; Wilke C
Phys Med Biol; 2023 Aug; 68(17):. PubMed ID: 37489861
[No Abstract] [Full Text] [Related]
18. Ovarian Mesonephric-Like Adenocarcinoma With Recurrent Liver Metastases: A Case Report with Analysis of Therapeutic Molecular Targets.
Sugitani A; Ogawa A; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2024 May; 32(3):578-585. PubMed ID: 37345348
[TBL] [Abstract] [Full Text] [Related]
19. Partial-Length Treatment With Brachytherapy in Patients With Endometrial cancer With High-Risk Features Is as Effective as Full-Length Vaginal Brachytherapy but With Reduced Toxicity.
Wernicke AG; Parashar B; Samuel E; Sabbas A; Gupta D; Caputo T
Pract Radiat Oncol; 2023; 13(5):e416-e422. PubMed ID: 37295725
[TBL] [Abstract] [Full Text] [Related]
20. Dose and secondary cancer-risk estimation of patients undergoing high dose rate intracavitary gynaecological brachytherapy.
Doudoo CO; Gyekye PK; Emi-Reynolds G; Adu S; Kpeglo DO; Nii Adu Tagoe S; Agyiri K
J Med Imaging Radiat Sci; 2023 Jun; 54(2):335-342. PubMed ID: 37087327
[TBL] [Abstract] [Full Text] [Related]
[Next]
